Home / Pfizer INC (PFE)
Pfizer INC
Forward trial catalysts linked to PFE
CSA tracks 22 forward catalysts for Pfizer INC across 17 assets, spanning Phase 3, Phase 2/3. The nearest is a readout expected Oct 30, 2026 (day precision). Confidence across its tracked catalysts breaks down as 22 medium. Tracked indications include Eczema, Atopic Dermatitis, Advanced Malignancies, and 29 more.
PFE in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Pfizer INC has:
Forward catalysts by year
2026 · 152027 · 112028 · 132029 · 122030 · 92032 · 3
Every catalyst in the snapshot comes with its date, date confidence and source link.
47 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| tucatinib | NCT03975647 | Phase 3 | Active, not recruiting | 2023-06-29 | Experimental | Seagen, a wholly owned subsidiary of Pfizer | HER2-positive Breast Cancer |
| vepdegestrant | NCT05654623 | Phase 3 | Active, not recruiting | 2025-01-31 | Experimental | Pfizer | Advanced Breast Cancer |
| encorafenib | NCT04607421 | Phase 3 | Active, not recruiting | 2025-03-01 | Experimental | Pfizer | Neoplasms |
| disitamab vedotin | NCT05980481 | Phase 2/3 | Active, not recruiting | 2025-07-10 | Experimental | RemeGen Co., Ltd. | Gastric Cancer |
| tucatinib | NCT05132582 | Phase 3 | Active, not recruiting | 2025-09-05 | Experimental | Seagen, a wholly owned subsidiary of Pfizer | HER2 Positive Breast Cancer |
| elranatamab | NCT05020236 | Phase 3 | Recruiting | 2026-02-26 | Experimental | Pfizer | Multiple Myeloma |
| elranatamab | NCT06152575 | Phase 3 | Recruiting | 2026-08-30 | Experimental | Pfizer | Multiple Myeloma |
| binimetinib | NCT04657991 catalyst | Phase 3 | Active, not recruiting | 2026-10-30 | Experimental | Pfizer | Melanoma |
| encorafenib | NCT04657991 catalyst | Phase 3 | Active, not recruiting | 2026-10-30 | Experimental | Pfizer | Melanoma |
| disitamab vedotin | NCT06221748 | Phase 2/3 | Recruiting | 2026-12 | Experimental | RemeGen Co., Ltd. | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma |
| mevrometostat | NCT06629779 catalyst | Phase 3 | Recruiting | 2026-12-02 | Experimental | Pfizer | Metastatic Castration-Resistant Prostate Cancer |
| ritlecitinib | NCT07029711 catalyst | Phase 3 | Active, not recruiting | 2026-12-02 | Experimental | Pfizer | Severe Alopecia Areata |
| mevrometostat | NCT06551324 catalyst | Phase 3 | Active, not recruiting | 2026-12-28 | Experimental | Pfizer | Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
| vepdegestrant | NCT05909397 catalyst | Phase 3 | Active, not recruiting | 2026-12-30 | Experimental | Pfizer | Breast Cancer |
| axitinib | NCT05059522 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | Pfizer | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors |
| lorlatinib | NCT05059522 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | Pfizer | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors |
| talazoparib | NCT05059522 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | Pfizer | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors |
| utomilumab | NCT05059522 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | Pfizer | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors |
| disitamab vedotin | NCT05302284 | Phase 3 | Recruiting | 2026-12-31 | Experimental | RemeGen Co., Ltd. | Urothelial Carcinoma; HER2-expressing |
| disitamab vedotin | NCT05911295 catalyst | Phase 3 | Active, not recruiting | 2027-01-29 | Experimental | Seagen, a wholly owned subsidiary of Pfizer | Urothelial Carcinoma |
| tofacitinib | NCT04624230 catalyst | Phase 3 | Active, not recruiting | 2027-03-17 | Experimental | Pfizer | Ulcerative Colitis |
| ritlecitinib | NCT06163326 catalyst | Phase 3 | Active, not recruiting | 2027-03-31 | Experimental | Pfizer | Vitiligo |
| abrocitinib | NCT06807268 catalyst | Phase 3 | Recruiting | 2027-05-02 | Experimental | Pfizer | Eczema |
| binimetinib | NCT05615818 | Phase 3 | Recruiting | 2027-06 | Experimental | UNICANCER | Biliary Tract Neoplasms |
| encorafenib | NCT05615818 | Phase 3 | Recruiting | 2027-06 | Experimental | UNICANCER | Biliary Tract Neoplasms |
| ritlecitinib | NCT06072183 catalyst | Phase 3 | Active, not recruiting | 2027-07-30 | Experimental | Pfizer | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo |
| elranatamab | NCT05317416 catalyst | Phase 3 | Active, not recruiting | 2027-08-04 | Experimental | Pfizer | Multiple Myeloma |
| disitamab vedotin | NCT04400695 | Phase 3 | Recruiting | 2027-12-31 | Experimental | RemeGen Co., Ltd. | Breast Cancer |
| tucatinib | NCT05253651 catalyst | Phase 3 | Recruiting | 2027-12-31 | Experimental | Seagen, a wholly owned subsidiary of Pfizer | Colorectal Neoplasms |
| ponsegromab | NCT06989437 catalyst | Phase 2/3 | Recruiting | 2028-01-23 | Experimental | Pfizer | Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma |
| tucatinib | NCT04457596 | Phase 3 | Active, not recruiting | 2028-01-31 | Experimental | Alliance for Clinical Trials in Oncology | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2 Po… |
| berobenatide | NCT07845500 catalyst | Phase 3 | Not yet recruiting | 2028-02-16 | Experimental | Pfizer | Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity |
| tilrekimig | NCT07765888 catalyst | Phase 3 | Recruiting | 2028-03-10 | Experimental | Pfizer | Atopic Dermatitis |
| berobenatide | NCT07792954 catalyst | Phase 3 | Not yet recruiting | 2028-03-14 | Experimental | Pfizer | Obesity; Overweight |
| ritlecitinib | NCT06873945 catalyst | Phase 3 | Recruiting | 2028-03-19 | Experimental | Pfizer | Alopecia Areata |
| ritlecitinib | NCT07733765 | Phase 3 | Recruiting | 2028-04-26 | Experimental | Pfizer | Alopecia Areata |
| berobenatide | NCT07823608 | Phase 3 | Recruiting | 2028-04-30 | Experimental | Pfizer | Apnea; Sleep Disorders; Overweight and/or Obesity |
| tilrekimig | NCT07783425 | Phase 3 | Not yet recruiting | 2028-08-29 | Experimental | Pfizer | Atopic Dermatitis |
| mevrometostat | NCT07028853 | Phase 3 | Recruiting | 2028-09-12 | Experimental | Pfizer | Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer… |
| berobenatide | NCT07794774 | Phase 3 | Not yet recruiting | 2029-02-21 | Experimental | Pfizer | Obesity |
| berobenatide | NCT07794761 | Phase 3 | Not yet recruiting | 2029-03-14 | Experimental | Pfizer | Obesity |
| abrocitinib | NCT07823595 | Phase 3 | Not yet recruiting | 2029-04-10 | Experimental | Pfizer | Atopic Dermatitis |
| tucatinib | NCT07413939 | Phase 2/3 | Recruiting | 2029-05-01 | Active comparator | Hoffmann-La Roche | HER2-positive Breast Cancer |
| disitamab vedotin | NCT07498907 | Phase 3 | Recruiting | 2029-05-01 | Experimental | Peking University First Hospital | Upper Tract Urothelial Carcinoma |
| tilrekimig | NCT07772921 | Phase 3 | Not yet recruiting | 2029-06-12 | Experimental | Pfizer | Asthma |
| disitamab vedotin | NCT07315750 | Phase 3 | Recruiting | 2029-06-30 | Experimental | RemeGen Co., Ltd. | Gastric Carcinoma |
| elranatamab | NCT07647432 | Phase 2/3 | Not yet recruiting | 2029-12-01 | Experimental | University of Illinois at Chicago | Plasmablastic Lymphoma; Hiv; Consolidation |
| ritlecitinib | NCT07029828 | Phase 3 | Recruiting | 2030-06-26 | Experimental | Pfizer | Severe Alopecia Areata |
| elranatamab | NCT05623020 | Phase 3 | Recruiting | 2030-10-18 | Experimental | Pfizer | Multiple Myeloma |
| abrocitinib | NCT06807281 | Phase 3 | Recruiting | 2032-02-22 | Experimental | Pfizer | Atopic Dermatitis |
| axitinib | NCT06364631 | Phase 3 | Recruiting | 2032-05-05 | Other | Gustave Roussy, Cancer Campus, Grand Paris | Metastatic Kidney Cancer; Metastatic Kidney Carcinoma |
| elranatamab | NCT06918002 | Phase 3 | Recruiting | 2036-05 | Experimental | Intergroupe Francophone du Myelome | Multiple Myeloma, Newly Diagnosed |
Every trial the CSA sample links to PFE's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
MelanomaBiliary Tract NeoplasmsNeoplasmsMetastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Castration-Resistant Prostate CancerMetastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateStable Nonsegmental VitiligoActive Nonsegmental VitiligoVitiligoAlopecia AreataSevere Alopecia AreataAdvanced Breast CancerBreast CancerAdvanced MalignanciesNSCLCOvarian CancerUrothelial CancerSolid TumorsMetastatic Kidney CancerMetastatic Kidney CarcinomaUrothelial CarcinomaHER2-expressingGastric CancerGastroesophageal Junction AdenocarcinomaGastric CarcinomaUpper Tract Urothelial CarcinomaUlcerative ColitisEczemaAtopic DermatitisMultiple MyelomaMultiple Myeloma, Newly DiagnosedPlasmablastic LymphomaHivConsolidationHER2-positive Breast CancerAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
and 16 more.
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →